News
Article
Author(s):
Dermatology Times is recapping our top expert interviews from the month of June.
Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.
James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.
Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.
Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.
Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.
James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.
The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.
Jason Hawkes, MD, MS, breaks down boxed warning pros and cons and research addressing several boxed warnings.
Lockshin shared his approach to continuing biologic therapies into pregnancy with informed timing adjustments.
James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.
Jason Hawkes, MD, MS, detailed each of the kinases' association with different cytokine receptors and biological functions.
Zabinski, vice president and head of commercial strategy and AI at OM1, discusses the evolving role of AI in dermatology, focusing on its potential and challenges in skin cancer detection.
Henry Lim, MD, discusses key findings and areas of improvement identified by the report, as well as his hopes for HS treatment moving forward.
Karan Lal, DO, MS, FAAD, is a double-board certified pediatric and cosmetic dermatologist at Affiliated Dermatology in Scottsdale, Arizona.
Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.
Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.
Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.
Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.
Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.
Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.
Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.
Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.
David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.
Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.
Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.
Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.
Aubrie Jones, PA-C, MMS, and Laura Bush, DMSc, PA-C, DFAAPA, discuss the role of the SDPA in supporting the growth and journeys of PAs at all stages.
Terry Arnold, PA-C, shares a wide range of opportunities to take clinical experience to a different setting and tips to transition.
Ethan Sims, MD, spoke with Dermatology Times on having positive conversations, cutting down on waste, and how to get involved in change.
Omar Noor, MD, and a patient with psoriasis share their unique perspectives on moderate to severe plaque psoriasis treatment with tildrakizumab.
Rob Casquejo, PA-C, spoke with Dermatology Times on new and upcoming medications, addressing unmet needs, and social media misinformation.
Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.
Patricia Richey, MD, delves into efficacy of the 1927 and 1550 nanometer lasers to prevent skin cancers.
Laura Bush reflects on her term as SDPA president, discussing achievements, challenges, and the future of dermatology PAs in health care.
The recent news of counterfeit Botox resulted in patients with blurred vision, difficulty swallowing, shortness of breath, and additional symptoms.
Martin Zaiac, MD, gave insight on potential risks associated with manipulation of nails, hygiene, and when it is necessary to see a specialist.
Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.
Stephen Tyring, MD, PhD, MBA, covers the burden of antimicrobial resistance and the need for alternative treatments.
Renata Block, MMS, PA-C, and Amber Blair, MMS, PA-C, discuss the gratification of helping patients and the excitement of being on the cutting edge of research.
Maryanne Makredes Senna, MD, shares insights into the complexities of treating alopecia areata and guidance for clinicians.
Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
